QuidelOrtho earnings beat by $0.11, revenue fell short of estimates

QuidelOrtho (QDEL) reported Q3 EPS of $0.31, beating estimates by $0.11, but revenue of $618.9M missed expectations. FY 2026 guidance: EPS $0.65-$0.90 (vs. consensus $0.77) and revenue $2.52B-$2.60B (vs. consensus $2.54B). Stock up 14.69% in 3 months, down 48.06% in 1 year.

Original reporting
Published Nov 3, 2026, 9:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$QDEL
Bearish
high confidence
Mentioned
$QDEL
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$QDELBearishMed
01

Why it matters

Earnings beat on EPS but revenue miss may cause short‑term volatility; guidance suggests upside if lower bound is met.

02

Market read

First‑report earnings data for QDEL; relevant for traders monitoring healthcare diagnostics earnings season.

03

What to watch

Guidance range still above consensus on the low end, offering upside potential if the company meets the lower bound.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

QuidelOrtho is a diagnostics company listed on NASDAQ. The article provides its latest quarterly results and FY guidance.

Company-level read

Ticker impact

$QDELBearishHigh confidence
Context

QDEL reported Q3 EPS $0.31 beating estimates by $0.11 and revenue $618.9M missing consensus, plus FY2026 guidance range.

Expected impact

likely modest downside pressure as revenue shortfall offsets EPS beat

Evidence & confidence

Investors often prioritize top‑line growth; the miss of $9.2M versus consensus may trigger sell‑offs despite the EPS beat.

Market effects

Healthcare diagnostics sector may see mixed reaction as peers watch QDEL's revenue shortfall.

U.S. market may see slight pullback in related biotech stocks.

Limited global impact; primarily U.S. investors.

Counterpoint

The EPS beat could signal underlying strength; price may rally on momentum despite revenue miss.

Key entities

  • QuidelOrtho

    NASDAQ‑listed diagnostics firm reporting Q3 results.

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.

$QDELHighAI 8/10

QuidelOrtho: Q3 Earnings Snapshot

QuidelOrtho (QDEL) reported a Q3 loss of $53.8M, or 78 cents per share, with adjusted earnings of 31 cents per share. Revenue was $618.9M. The company expects full-year earnings of 65-70 cents per share and revenue of $2.52B-$2.54B, according to its Tuesday report.